The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use of the Peregrine System Kit (Ablative Solutions) in renal denervation.
Target BP I is a blinded, randomised sham-controlled study that is evaluating the safety and efficacy of the system in the treatment of patients with uncontrolled hypertension who are taking two to five anti-hypertensive medications.
The company announced the trial’s commencement in a press release, which explains that the TARGET BP I trial and the ongoing European TARGET-BP OFF-MED trial are part of the TARGET BP clinical trials programme and are designed to evaluate the safety and efficacy of the Peregrine System Kit when used to treat patients with uncontrolled hypertension. The system is comprised of a patented infusion catheter and dehydrated alcohol.
David Kandzari (Piedmont Heart Institute, Atlanta, USA) co-principal investigator of the TARGET BP I trial, comments in the release: “It is exciting to initiate this important trial to evaluate the Peregrine System Kit for the treatment of patients with uncontrolled hypertension. More than half of those treated with antihypertensive medications do not achieve their target blood pressure, so there is a great need for improved therapeutic options.”
Source VascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389